Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Juli 2022 - 12:45PM
Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on
developing next-generation therapeutics for difficult-to-treat
cancers, reported on July 1, 2022 that Pyxis Oncology’s Board of
Directors granted restricted stock units with respect to an
aggregate of 61,360 shares of Pyxis Oncology’s common stock and
stock options to purchase an aggregate of 76,701 shares of Pyxis
Oncology’s common stock to four newly hired employees. The awards
were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan
with a grant date of July 1, 2022, as an inducement material to the
new employee entering employment with Pyxis Oncology, in accordance
with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units and stock options vest over four
years, with 25% vesting on the first anniversary of the vesting
commencement date for each employee and the remainder vesting in 36
substantially-equal monthly installments thereafter, subject to
each employee’s continuous service with Pyxis Oncology through each
vesting date. The stock options have a ten-year term and an
exercise price of $2.44, the closing price of Pyxis Oncology’s
common stock as reported by Nasdaq on July 1, 2022.
Pyxis Oncology is providing this information in accordance with
Nasdaq Listing Rule 5635(c)(4).
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is focused on defeating difficult to treat
cancers and improving patient lives. By leveraging our fully
integrated research, development and commercial capabilities, our
expert team is efficiently building a diversified portfolio of
next-generation therapeutics. Pyxis Oncology’s therapeutic
candidates are designed to directly kill tumor cells, and to
address the underlying pathologies created by cancer that enable
its uncontrollable proliferation and immune evasion. Since its
launch in 2019, Pyxis Oncology has developed a broad portfolio of
novel antibody drug conjugate, or ADC, product candidates, and
monoclonal antibody, or mAb, preclinical discovery programs that it
is developing as monotherapies and in combination with other
therapies. To learn more about Pyxis Oncology visit
www.pyxisoncology.com.
Pyxis Oncology Contact:Courtney DuganVice
President, Head of Investor Relations & Corporate
Communications(617) 500-8872ir@pyxisoncology.com
Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart
Von Mär 2024 bis Mai 2024
Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024